A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects with Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors

Type of Cancer
Solid Tumor

Site
Hackensack

Sponsor
Sarah Cannon

Protocol Number
Trillium-TTI-621-01

Phase of Trial
Phase I

To Learn More Call
(201)-510-0950